The investigation, led by Yu Hasegawa of the Women’s Biomedical Research Institute at the Icahn School of Medicine at Mount Sinai, together with colleagues at the University of Maryland School of Medicine and other institutions, focused on bacterial extracellular vesicles, or bEVs. These are nanoscale, membrane-bound packages that bacteria shed continuously, carrying proteins, toxins, DNA, RNA, and fragments of cell-wall components. Far from being inert debris, bEVs act as messengers: they travel through the mucus and fluid lining the vaginal tract, dock onto epithelial and immune cells, and deliver molecular signals that can calm or inflame the host. In effect, they form a communication network layered on top of the microbiome itself, and it is this network that the new work shows is scrambled by antibiotic exposure.

The team worked with three species that define very different vaginal states. Lactobacillus crispatus dominates a healthy vaginal microbiome, classified as Community State Type I, and its presence is associated with low inflammation and protection against infection. By contrast, microbiomes dominated by anaerobes such as Gardnerella vaginalis and Mobiluncus mulieris, known as Community State Type IV, are linked to bacterial vaginosis and to serious downstream consequences, including increased susceptibility to sexually transmitted infections, infertility, and preterm birth. Understanding how these species signal to host tissue, and how treatment alters that signaling, is therefore central to explaining why bacterial vaginosis so often recurs after antibiotic therapy.

To probe this, the researchers grew each species in the laboratory and exposed cultures to three clinically relevant antibiotics, ampicillin, clindamycin, and metronidazole, at doses below the minimum inhibitory concentration, the threshold normally required to stop bacterial growth. This sub-minimal dosing was deliberate: in a real vaginal environment, antibiotic concentrations vary widely across time and space, and bacteria in protected niches frequently experience levels that stress rather than kill them. The team then isolated the vesicles released by treated and untreated cultures and quantified them using nanoparticle tracking analysis, a laser-based technique that counts and sizes individual nanoparticles in suspension.

The isolated vesicles were next applied to laboratory cultures of human epithelial and immune cells, and the inflammatory response was measured with cytokine profiling using multiplex immunoassays, which can quantify dozens of immune signaling molecules simultaneously. The researchers also performed Toll-like receptor pathway analyses. Toll-like receptors are pattern-recognition molecules on the surface of host cells that detect conserved microbial structures such as lipoproteins and flagellin, and they sit at the front line of innate immunity, deciding whether a bacterial signal is interpreted as benign or threatening.

The results were striking and highly specific. Antibiotic exposure significantly enhanced the inflammatory properties of the vesicles, but the effect depended on both the bacterial species and the antibiotic involved. Vesicles from antibiotic-exposed Gardnerella vaginalis cultures provoked elevated cytokine responses in host cells primarily through activation of TLR2, the receptor that recognizes bacterial lipoproteins. Vesicles from Mobiluncus mulieris, meanwhile, stimulated inflammation through both TLR2 and TLR5, the latter being the receptor dedicated to detecting flagellin, the protein that builds bacterial tails. These findings indicate that the drugs do not merely reduce bacterial numbers; they change the molecular cargo and immune visibility of the vesicles the surviving bacteria release.

Perhaps the most unexpected result concerned Lactobacillus crispatus. Vesicles from this beneficial species are typically non-inflammatory, consistent with its role in maintaining a calm vaginal environment. Yet when the cultures were exposed to metronidazole, the workhorse drug for bacterial vaginosis, even at a dose lower than what is used clinically, the resulting vesicles became immunostimulatory. In other words, a treatment intended to restore vaginal health may inadvertently push its most protective resident into producing inflammatory signals, an unintended proinflammatory consequence that could help explain why some patients feel worse before they feel better, and why the microbial ecosystem sometimes fails to settle back into a healthy state after therapy.

The study did not stop at laboratory cultures. Examining human vaginal swabs, the researchers detected bacterial extracellular vesicles directly in patient samples, including vesicles carrying vaginolysin, a toxin characteristic of Gardnerella. Notably, such vesicles were found even in swabs from women whose microbiomes were classified as Community State Type I, dominated by Lactobacillus. This indicates that low-abundance microbes, including potential pathogens, remain transcriptionally active even when they are too scarce to register in standard microbiome profiling, quietly releasing vesicles that continue to shape the local immune environment. The vesicle layer, in other words, preserves a memory of the microbial community that simple bacterial census methods miss.

Taken together, the findings suggest that antibiotics reshape bacterial communication in the vagina through their vesicles, potentially contributing to inflammation, disruption of the epithelial barrier that protects underlying tissue, persistent dysbiosis, and the recurrent infections that plague bacterial vaginosis patients. The authors argue that the work underscores the need for precision antimicrobial strategies that eliminate pathogens while preserving beneficial bacteria and their functional vesicles. Future therapies, they suggest, should account for the ecosystem-wide effects of antibiotics on the vaginal microbiome and on the vesicle-mediated signaling network that connects microbes to host immunity. Given the high recurrence rates of bacterial vaginosis and its links to preterm birth and infection risk, treating the vaginal microbiome as an ecosystem to be managed, rather than a pathogen to be eradicated, may prove a decisive shift in women’s health.

Subject of Research: Antibiotic-driven changes in the immune profiles of bacterial extracellular vesicles from vaginal anaerobes

Article Title: Exposure to antibiotics modifies the immune profiles of bacterial extracellular vesicles from common vaginal anaerobes

Article References: Hasegawa, Y., Swain, O., Rajpal, U., France, M., Ncube, L., Mogno, I., Zierden, H., Ravel, J., & Elovitz, M. A. (2026). Exposure to antibiotics modifies the immune profiles of bacterial extracellular vesicles from common vaginal anaerobes. Microbiome. https://doi.org/10.1186/s40168-026-02510-w

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02510-w

Keywords: vaginal microbiome, bacterial extracellular vesicles, bacterial vaginosis, Gardnerella vaginalis, Lactobacillus crispatus, Mobiluncus mulieris, metronidazole, clindamycin, Toll-like receptors, inflammation, dysbiosis, preterm birth

At the heart of the review is a deceptively simple proposition: sexually transmitted infections do not emerge in a biological vacuum. The vaginal microbiome, or VMB, is a complex community of microorganisms whose composition varies dramatically from person to person. In many individuals, the ecosystem is dominated by Lactobacillus species, particularly Lactobacillus crispatus, which maintain a low-pH environment hostile to pathogens. In others, the community shifts toward Lactobacillus iners or toward diverse assemblages of anaerobic bacteria such as Gardnerella vaginalis. These shifts are not random. They fluctuate with hormonal milestones, menstrual cycles, sexual behaviour, race, ethnicity, body mass index, stress and a host of other factors, many of which lie outside an individual’s personal control.

The authors emphasize that this variability matters clinically. Different VMB compositions appear to influence susceptibility to STI acquisition and transmission, yet the precise relationships between microbial composition, the vaginal microenvironment and infection outcomes remain poorly characterized, particularly for women and gender-diverse people. Vaginal STI infections are also less likely to produce noticeable symptoms than infections in other anatomical sites, which means that women and gender-diverse individuals have often been overlooked as potential reservoirs of STIs within broader sexual networks. This gap in surveillance and understanding, the authors contend, is not merely an academic oversight but a public health vulnerability.

The review arrives at a moment of genuine urgency for sexual health policy. In Australia, doxycycline post-exposure prophylaxis, or Doxy-PEP, has recently become available to gay and bisexual men who have sex with men, a population in which AMR-STIs such as resistant Neisseria gonorrhoeae are highly prevalent. The intervention involves taking the antibiotic doxycycline proactively after sex to prevent infection, and early evidence suggests it can reduce STI acquisition in the groups studied. But the Australian guidelines exclude people assigned female at birth and fail to specify how the intervention should be applied to gender-diverse individuals. That exclusion creates a striking asymmetry: one segment of a sexual network receives prophylactic antibiotics while their partners do not, a situation the authors argue demands rigorous investigation of downstream effects.

From a microbiological standpoint, the concern is well grounded. Antimicrobial resistance does not simply appear; it is selected for. The review describes the vaginal microenvironment as, hypothetically, a near-perfect platform for the development and emergence of AMR-STIs. Bacteria within the VMB can form biofilms, structured communities encased in extracellular polymeric substances that function as a kind of biological glue. Biofilms concentrate microorganisms in close physical proximity, creating abundant opportunities for horizontal gene transfer, the process by which microbes exchange genetic material, including antimicrobial resistance genes. A pathogen such as N. gonorrhoeae, encountering a vaginal biofilm rich in resistant commensal organisms, could in principle acquire resistance genes that would otherwise remain sequestered in harmless residents.

The authors also point to the delicate balance that defines VMB health. The ecosystem exists in a continuous negotiation between protective Lactobacillus dominance and opportunistic pathogens poised to exploit any disturbance. Antibiotic exposure is precisely such a disturbance. When antibiotics are deployed prophylactically in one part of a sexual network, the microbiomes of untreated partners may nonetheless experience ecological knock-on effects through repeated exposure to resistant organisms, altered transmission dynamics and the selective pressures created by partners’ antibiotic use. The review stresses that antimicrobial treatments applied to specific population groups can themselves act as selective pressures for AMR-STIs and require pragmatic study that accounts for these downstream consequences.

What distinguishes this review from much of the existing literature is its insistence on the social dimension of microbial ecology. Sex, gender and sexuality, the authors write, are inextricably linked and highly relevant to STIs, and global patterns of sexual and reproductive health correlate strongly with the socioeconomic status of a country or community. Sexual networks are not abstract mathematical constructs; they are shaped by identity, behaviour, stigma and access to care. The review highlights how race and ethnicity influence VMB composition, how lifestyle factors and menstrual milestones reshape the microbial balance over time, and how systematic historical neglect has left women and sexuality and gender diverse minorities with gaps in both scientific understanding and medical treatment options.

The authors extend their analysis to populations rarely considered in microbiome research. People assigned female at birth are joined by transgender women with neovaginas, whose surgically constructed anatomy hosts a neovaginal microbiome that is notably distinct from that of the vagina, yet is rarely studied in its own right. Hormone replacement therapy, testosterone-dominant physiology and oestrogen-dominant physiology each produce different microbial milieus, yet clinical guidance seldom addresses these variations. Women who have sex with women constitute another understudied group within STI research, despite participating in sexual networks where infections circulate. The cumulative effect of these omissions, the review argues, is a medical landscape in which treatments are designed, tested and approved on the basis of evidence that may not apply to the very patients receiving them.

The technical framework underpinning the argument draws on classical microbial ecology. The vaginal microbiome is treated as an ecological niche, a micro-ecology in which environmental conditions, microbial co-inhabitants and host physiology interact continuously. Oestrogen-dominant VMBs, for example, tend to favour glycogen deposition in the vaginal epithelium, which in turn supports Lactobacillus growth and acidification. Disturbances to this equilibrium, whether through antibiotics, hormonal shifts or sexual exposure, can trigger transitions between community states, some of which are associated with bacterial vaginosis, vulvovaginal candidiasis, urinary tract infections and heightened STI susceptibility. Each transition reshapes the landscape of gene exchange and pathogen survival within the niche.

The review does not claim to have demonstrated that the vaginal microbiome is driving AMR-STI emergence. Rather, it assembles converging lines of evidence and identifies where the knowledge gaps lie. How does VMB composition affect the efficiency of horizontal gene transfer involving STI pathogens in vivo? Do biofilm-forming anaerobes serve as reservoirs of resistance genes that can be mobilized into pathogens? How do prophylactic antibiotic programs aimed at one population influence resistance dynamics in the untreated partners of that population? None of these questions, the authors argue, can be answered without research that simultaneously attends to microbial ecology and social context, because the two are intertwined at every level.

The authors call for a research agenda that centres the populations long excluded from sexual health science. They urge study of how intersecting social, sexual, behavioural and biological factors shape STI risk within the vaginal microbiome, how these factors operate for sexuality and gender diverse individuals, and ultimately how the combination influences the trajectory of AMR-STI evolution. Given the global spread of resistant gonorrhoea and the growing spectre of untreatable infections, the stakes of such research extend well beyond any single country or community.

In framing the vagina as both a microbial ecosystem and a socially embedded one, the review offers a perspective that is likely to resonate far beyond microbiology. Public health interventions that ignore ecology risk selecting for the very threats they aim to prevent, and interventions that ignore social reality risk leaving the most vulnerable populations unprotected and unstudied. The vaginal microbiome, the authors suggest, sits precisely at the intersection of these failures, and understanding it may prove essential to keeping drug-resistant STIs in check. Until the microbial and the social are studied together, the conditions favouring AMR-STI emergence may quietly persist, invisible in laboratory data and policy documents alike, thriving in the gap between how infections are treated and how people actually live.